<?xml version="1.0" encoding="UTF-8" ?>
<oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>A bioengineering approach for corneal endothelial regeneration.</dc:title>
<dc:creator>Bosch Canals, Begoña María</dc:creator>
<dc:contributor>Pérez Antoñanzas, Roman</dc:contributor>
<dc:contributor>Gil Mur, Javier</dc:contributor>
<dc:contributor>Sabater, Alfonso</dc:contributor>
<dc:contributor>Universitat Internacional de Catalunya. Departament de Ciències Bàsiques</dc:contributor>
<dc:subject>Tissue engineering</dc:subject>
<dc:subject>Corneal endothelium</dc:subject>
<dc:subject>Regenerative medicine</dc:subject>
<dc:subject>Bioingeniería y medicina regenerativa</dc:subject>
<dc:subject>61</dc:subject>
<dc:description>Nowadays, there are approximately 10 million people worldwide with visual impairment due to corneal diseases. Currently, the main therapeutic solution is the transplant of a donor's cornea. The great majority of transplants is due to some failure in the inner layer of the cornea, which is called the corneal endothelium and this is mainly related with the inability of this layer to regenerate in vivo. However, transplants present several limitations such as the low number of healthy donors or immunological rejection by the patient. In order to overcome these problems, several researchers have focused in culturing corneal endothelial cells (CEC) to subsequently replace non-functional CEC. However, cell therapy is still very recent and still presents a series of drawbacks. For instance, using animal CEC or cells from other patients has shown to lead into immunological rejection. In order to avoid this, it is possible to use stem cells from the same patient, which have the ability to differentiate into many cell types, including the corneal endothelium. Currently, the stem cells used to regenerate CEC are mainly pluripotent stem cells, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC), which are derived from adult cells. Despite their great potential for treating diseases, these types of stem cells present major limitations such as the risk of teratoma formation. In addition, they present other disadvantages such as ethical problems associated with the use of ESCs, safety problems related to iPSC since they requires the use of virus for their production hence limiting its clinical application. For this reason, and in order to solve the current problems in the regeneration of corneal endothelium, this thesis project uses dental pulp stem cells (DPSC) for the formation of CEC. DPSC are an accessible source derived from the same patient, avoiding possible future problems of rejection. In addition, the use of DPSC avoids the ethical and security problems associated with ESC and iPSC. Furthermore, DPSC and CEC have the same embryological origin, as they both arise from neural crest stem cells. In fact, DPSC express neural crest stem cells markers, which facilitates their differentiation into neural crest stem cells (NCSC), which is an intermediate step for the formation of CEC. Therefore, this thesis project uses a two-step protocol, where DPSC are differentiated into NCSC and, subsequently, NCSC are derived into CEC. Because the use of cell therapies alone may present limited cell viability once it is injected, the field of tissue engineering is a new discipline that has appeared to overcome this limitation. Tissue engineering combines the use of cells, biomaterials and biological molecules. It has been demonstrated that the use of different topographies in cell culture modulates cell behavior, and may have an effect on their functionality, cell distribution or cell size. Therefore, this thesis project applies tissue engineering as another strategy for the generation of functional CEC with its characteristic phenotype and morphology. For doing this, we have mimicked the natural CEC environment by cultivating the cells on substrates with different curvatures, composition or topographies that are able to mimic those of the human eye. In conclusion, this thesis project proposes the use of bioengineering, by differentiating CEC from stem cells derived from the patient and the use of biomaterials with different topographies and curvatures, for the regeneration of corneal endothelium.</dc:description>
<dc:date>2019-07-16</dc:date>
<dc:type>info:eu-repo/semantics/doctoralThesis</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:identifier>http://hdl.handle.net/10803/667398</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights>L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:format>application/pdf</dc:format>
<dc:format>206 p.</dc:format>
<dc:publisher>Universitat Internacional de Catalunya</dc:publisher>
<dc:source>TDX (Tesis Doctorals en Xarxa)</dc:source>
</oai_dc:dc>
<?xml version="1.0" encoding="UTF-8" ?>
<dim:dim schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
<dim:field element="contributor" mdschema="dc">Universitat Internacional de Catalunya. Departament de Ciències Bàsiques</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="author">Bosch Canals, Begoña María</dim:field>
<dim:field element="contributor" lang="en_US" mdschema="dc" qualifier="authoremail">bbosch@uic.es</dim:field>
<dim:field element="contributor" lang="en_US" mdschema="dc" qualifier="authoremailshow">false</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="director">Pérez Antoñanzas, Roman</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="director">Gil Mur, Javier</dim:field>
<dim:field element="contributor" mdschema="dc" qualifier="director">Sabater, Alfonso</dim:field>
<dim:field element="date" mdschema="dc" qualifier="accessioned">2019-07-31T14:27:12Z</dim:field>
<dim:field element="date" mdschema="dc" qualifier="available">2021-07-15T02:00:13Z</dim:field>
<dim:field element="date" mdschema="dc" qualifier="issued">2019-07-16</dim:field>
<dim:field element="identifier" mdschema="dc" qualifier="uri">http://hdl.handle.net/10803/667398</dim:field>
<dim:field element="description" lang="en_US" mdschema="dc" qualifier="abstract">Nowadays, there are approximately 10 million people worldwide with visual impairment due to corneal diseases. Currently, the main therapeutic solution is the transplant of a donor's cornea. The great majority of transplants is due to some failure in the inner layer of the cornea, which is called the corneal endothelium and this is mainly related with the inability of this layer to regenerate in vivo. However, transplants present several limitations such as the low number of healthy donors or immunological rejection by the patient. In order to overcome these problems, several researchers have focused in culturing corneal endothelial cells (CEC) to subsequently replace non-functional CEC. However, cell therapy is still very recent and still presents a series of drawbacks. For instance, using animal CEC or cells from other patients has shown to lead into immunological rejection. In order to avoid this, it is possible to use stem cells from the same patient, which have the ability to differentiate into many cell types, including the corneal endothelium. Currently, the stem cells used to regenerate CEC are mainly pluripotent stem cells, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC), which are derived from adult cells. Despite their great potential for treating diseases, these types of stem cells present major limitations such as the risk of teratoma formation. In addition, they present other disadvantages such as ethical problems associated with the use of ESCs, safety problems related to iPSC since they requires the use of virus for their production hence limiting its clinical application. For this reason, and in order to solve the current problems in the regeneration of corneal endothelium, this thesis project uses dental pulp stem cells (DPSC) for the formation of CEC. DPSC are an accessible source derived from the same patient, avoiding possible future problems of rejection. In addition, the use of DPSC avoids the ethical and security problems associated with ESC and iPSC. Furthermore, DPSC and CEC have the same embryological origin, as they both arise from neural crest stem cells. In fact, DPSC express neural crest stem cells markers, which facilitates their differentiation into neural crest stem cells (NCSC), which is an intermediate step for the formation of CEC. Therefore, this thesis project uses a two-step protocol, where DPSC are differentiated into NCSC and, subsequently, NCSC are derived into CEC. Because the use of cell therapies alone may present limited cell viability once it is injected, the field of tissue engineering is a new discipline that has appeared to overcome this limitation. Tissue engineering combines the use of cells, biomaterials and biological molecules. It has been demonstrated that the use of different topographies in cell culture modulates cell behavior, and may have an effect on their functionality, cell distribution or cell size. Therefore, this thesis project applies tissue engineering as another strategy for the generation of functional CEC with its characteristic phenotype and morphology. For doing this, we have mimicked the natural CEC environment by cultivating the cells on substrates with different curvatures, composition or topographies that are able to mimic those of the human eye. In conclusion, this thesis project proposes the use of bioengineering, by differentiating CEC from stem cells derived from the patient and the use of biomaterials with different topographies and curvatures, for the regeneration of corneal endothelium.</dim:field>
<dim:field element="format" lang="en_US" mdschema="dc" qualifier="extent">206 p.</dim:field>
<dim:field element="format" mdschema="dc" qualifier="mimetype">application/pdf</dim:field>
<dim:field element="language" lang="en_US" mdschema="dc" qualifier="iso">eng</dim:field>
<dim:field element="publisher" mdschema="dc">Universitat Internacional de Catalunya</dim:field>
<dim:field element="rights" mdschema="dc" qualifier="license">L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</dim:field>
<dim:field element="rights" mdschema="dc" qualifier="accessLevel">info:eu-repo/semantics/openAccess</dim:field>
<dim:field element="source" mdschema="dc">TDX (Tesis Doctorals en Xarxa)</dim:field>
<dim:field element="subject" lang="en_US" mdschema="dc">Tissue engineering</dim:field>
<dim:field element="subject" lang="en_US" mdschema="dc">Corneal endothelium</dim:field>
<dim:field element="subject" lang="en_US" mdschema="dc">Regenerative medicine</dim:field>
<dim:field element="subject" lang="en_US" mdschema="dc" qualifier="other">Bioingeniería y medicina regenerativa</dim:field>
<dim:field element="subject" lang="en_US" mdschema="dc" qualifier="udc">61</dim:field>
<dim:field element="title" lang="en_US" mdschema="dc">A bioengineering approach for corneal endothelial regeneration.</dim:field>
<dim:field element="type" mdschema="dc">info:eu-repo/semantics/doctoralThesis</dim:field>
<dim:field element="type" mdschema="dc">info:eu-repo/semantics/publishedVersion</dim:field>
<dim:field element="embargo" lang="en_US" mdschema="dc" qualifier="terms">24 mesos</dim:field>
</dim:dim>
<?xml version="1.0" encoding="UTF-8" ?>
<thesis schemaLocation="http://www.ndltd.org/standards/metadata/etdms/1.0/ http://www.ndltd.org/standards/metadata/etdms/1.0/etdms.xsd">
<title>A bioengineering approach for corneal endothelial regeneration.</title>
<creator>Bosch Canals, Begoña María</creator>
<contributor>bbosch@uic.es</contributor>
<contributor>false</contributor>
<contributor>Pérez Antoñanzas, Roman</contributor>
<contributor>Gil Mur, Javier</contributor>
<contributor>Sabater, Alfonso</contributor>
<subject>Tissue engineering</subject>
<subject>Corneal endothelium</subject>
<subject>Regenerative medicine</subject>
<description>Nowadays, there are approximately 10 million people worldwide with visual impairment due to corneal diseases. Currently, the main therapeutic solution is the transplant of a donor's cornea. The great majority of transplants is due to some failure in the inner layer of the cornea, which is called the corneal endothelium and this is mainly related with the inability of this layer to regenerate in vivo. However, transplants present several limitations such as the low number of healthy donors or immunological rejection by the patient. In order to overcome these problems, several researchers have focused in culturing corneal endothelial cells (CEC) to subsequently replace non-functional CEC. However, cell therapy is still very recent and still presents a series of drawbacks. For instance, using animal CEC or cells from other patients has shown to lead into immunological rejection. In order to avoid this, it is possible to use stem cells from the same patient, which have the ability to differentiate into many cell types, including the corneal endothelium. Currently, the stem cells used to regenerate CEC are mainly pluripotent stem cells, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC), which are derived from adult cells. Despite their great potential for treating diseases, these types of stem cells present major limitations such as the risk of teratoma formation. In addition, they present other disadvantages such as ethical problems associated with the use of ESCs, safety problems related to iPSC since they requires the use of virus for their production hence limiting its clinical application. For this reason, and in order to solve the current problems in the regeneration of corneal endothelium, this thesis project uses dental pulp stem cells (DPSC) for the formation of CEC. DPSC are an accessible source derived from the same patient, avoiding possible future problems of rejection. In addition, the use of DPSC avoids the ethical and security problems associated with ESC and iPSC. Furthermore, DPSC and CEC have the same embryological origin, as they both arise from neural crest stem cells. In fact, DPSC express neural crest stem cells markers, which facilitates their differentiation into neural crest stem cells (NCSC), which is an intermediate step for the formation of CEC. Therefore, this thesis project uses a two-step protocol, where DPSC are differentiated into NCSC and, subsequently, NCSC are derived into CEC. Because the use of cell therapies alone may present limited cell viability once it is injected, the field of tissue engineering is a new discipline that has appeared to overcome this limitation. Tissue engineering combines the use of cells, biomaterials and biological molecules. It has been demonstrated that the use of different topographies in cell culture modulates cell behavior, and may have an effect on their functionality, cell distribution or cell size. Therefore, this thesis project applies tissue engineering as another strategy for the generation of functional CEC with its characteristic phenotype and morphology. For doing this, we have mimicked the natural CEC environment by cultivating the cells on substrates with different curvatures, composition or topographies that are able to mimic those of the human eye. In conclusion, this thesis project proposes the use of bioengineering, by differentiating CEC from stem cells derived from the patient and the use of biomaterials with different topographies and curvatures, for the regeneration of corneal endothelium.</description>
<date>2019-07-31</date>
<date>2021-07-15</date>
<date>2019-07-16</date>
<type>info:eu-repo/semantics/doctoralThesis</type>
<type>info:eu-repo/semantics/publishedVersion</type>
<identifier>http://hdl.handle.net/10803/667398</identifier>
<language>eng</language>
<rights>L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</rights>
<rights>info:eu-repo/semantics/openAccess</rights>
<publisher>Universitat Internacional de Catalunya</publisher>
<source>TDX (Tesis Doctorals en Xarxa)</source>
</thesis>
<?xml version="1.0" encoding="UTF-8" ?>
<record schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
<leader>00925njm 22002777a 4500</leader>
<datafield ind1=" " ind2=" " tag="042">
<subfield code="a">dc</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="720">
<subfield code="a">Bosch Canals, Begoña María</subfield>
<subfield code="e">author</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="260">
<subfield code="c">2019-07-16</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="520">
<subfield code="a">Nowadays, there are approximately 10 million people worldwide with visual impairment due to corneal diseases. Currently, the main therapeutic solution is the transplant of a donor's cornea. The great majority of transplants is due to some failure in the inner layer of the cornea, which is called the corneal endothelium and this is mainly related with the inability of this layer to regenerate in vivo. However, transplants present several limitations such as the low number of healthy donors or immunological rejection by the patient. In order to overcome these problems, several researchers have focused in culturing corneal endothelial cells (CEC) to subsequently replace non-functional CEC. However, cell therapy is still very recent and still presents a series of drawbacks. For instance, using animal CEC or cells from other patients has shown to lead into immunological rejection. In order to avoid this, it is possible to use stem cells from the same patient, which have the ability to differentiate into many cell types, including the corneal endothelium. Currently, the stem cells used to regenerate CEC are mainly pluripotent stem cells, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC), which are derived from adult cells. Despite their great potential for treating diseases, these types of stem cells present major limitations such as the risk of teratoma formation. In addition, they present other disadvantages such as ethical problems associated with the use of ESCs, safety problems related to iPSC since they requires the use of virus for their production hence limiting its clinical application. For this reason, and in order to solve the current problems in the regeneration of corneal endothelium, this thesis project uses dental pulp stem cells (DPSC) for the formation of CEC. DPSC are an accessible source derived from the same patient, avoiding possible future problems of rejection. In addition, the use of DPSC avoids the ethical and security problems associated with ESC and iPSC. Furthermore, DPSC and CEC have the same embryological origin, as they both arise from neural crest stem cells. In fact, DPSC express neural crest stem cells markers, which facilitates their differentiation into neural crest stem cells (NCSC), which is an intermediate step for the formation of CEC. Therefore, this thesis project uses a two-step protocol, where DPSC are differentiated into NCSC and, subsequently, NCSC are derived into CEC. Because the use of cell therapies alone may present limited cell viability once it is injected, the field of tissue engineering is a new discipline that has appeared to overcome this limitation. Tissue engineering combines the use of cells, biomaterials and biological molecules. It has been demonstrated that the use of different topographies in cell culture modulates cell behavior, and may have an effect on their functionality, cell distribution or cell size. Therefore, this thesis project applies tissue engineering as another strategy for the generation of functional CEC with its characteristic phenotype and morphology. For doing this, we have mimicked the natural CEC environment by cultivating the cells on substrates with different curvatures, composition or topographies that are able to mimic those of the human eye. In conclusion, this thesis project proposes the use of bioengineering, by differentiating CEC from stem cells derived from the patient and the use of biomaterials with different topographies and curvatures, for the regeneration of corneal endothelium.</subfield>
</datafield>
<datafield ind1="8" ind2=" " tag="024">
<subfield code="a">http://hdl.handle.net/10803/667398</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="653">
<subfield code="a">Tissue engineering</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="653">
<subfield code="a">Corneal endothelium</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="653">
<subfield code="a">Regenerative medicine</subfield>
</datafield>
<datafield ind1="0" ind2="0" tag="245">
<subfield code="a">A bioengineering approach for corneal endothelial regeneration.</subfield>
</datafield>
</record>
<?xml version="1.0" encoding="UTF-8" ?>
<record schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
<leader>nam a 5i 4500</leader>
<datafield ind1=" " ind2=" " tag="653">
<subfield code="a">Tissue engineering</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="653">
<subfield code="a">Corneal endothelium</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="653">
<subfield code="a">Regenerative medicine</subfield>
</datafield>
<datafield ind1="1" ind2="0" tag="245">
<subfield code="a">A bioengineering approach for corneal endothelial regeneration.</subfield>
</datafield>
<datafield ind1=" " ind2="1" tag="264">
<subfield code="a">[Barcelona] :</subfield>
<subfield code="b">Universitat Internacional de Catalunya,</subfield>
<subfield code="c">2019</subfield>
</datafield>
<datafield ind1="4" ind2="0" tag="856">
<subfield code="z">Accés lliure</subfield>
<subfield code="u">http://hdl.handle.net/10803/667398</subfield>
</datafield>
<controlfield tag="007">cr |||||||||||</controlfield>
<controlfield tag="008">AAMMDDs2019 sp ||||fsm||||0|| 0 eng|c</controlfield>
<datafield ind1="1" ind2=" " tag="100">
<subfield code="a">Bosch Canals, Begoña María,</subfield>
<subfield code="e">autor</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="300">
<subfield code="a">1 recurs en línia (206 pàgines)</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="502">
<subfield code="g">Tesi</subfield>
<subfield code="b">Doctorat</subfield>
<subfield code="c">Universitat Internacional de Catalunya. Departament de Ciències Bàsiques</subfield>
<subfield code="d">2019</subfield>
</datafield>
<datafield ind1="2" ind2=" " tag="710">
<subfield code="a">Universitat Internacional de Catalunya. Departament de Ciències Bàsiques</subfield>
</datafield>
<datafield ind1=" " ind2="4" tag="655">
<subfield code="a">Tesis i dissertacions electròniques</subfield>
</datafield>
<datafield ind1="1" ind2=" " tag="700">
<subfield code="a">Pérez Antoñanzas, Roman,</subfield>
<subfield code="e">supervisor acadèmic</subfield>
</datafield>
<datafield ind1="1" ind2=" " tag="700">
<subfield code="a">Gil Mur, Javier,</subfield>
<subfield code="e">supervisor acadèmic</subfield>
</datafield>
<datafield ind1="1" ind2=" " tag="700">
<subfield code="a">Sabater, Alfonso,</subfield>
<subfield code="e">supervisor acadèmic</subfield>
</datafield>
<datafield ind1="0" ind2=" " tag="730">
<subfield code="a">TDX</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="520">
<subfield code="a">Nowadays, there are approximately 10 million people worldwide with visual impairment due to corneal diseases. Currently, the main therapeutic solution is the transplant of a donor's cornea. The great majority of transplants is due to some failure in the inner layer of the cornea, which is called the corneal endothelium and this is mainly related with the inability of this layer to regenerate in vivo. However, transplants present several limitations such as the low number of healthy donors or immunological rejection by the patient. In order to overcome these problems, several researchers have focused in culturing corneal endothelial cells (CEC) to subsequently replace non-functional CEC. However, cell therapy is still very recent and still presents a series of drawbacks. For instance, using animal CEC or cells from other patients has shown to lead into immunological rejection. In order to avoid this, it is possible to use stem cells from the same patient, which have the ability to differentiate into many cell types, including the corneal endothelium. Currently, the stem cells used to regenerate CEC are mainly pluripotent stem cells, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC), which are derived from adult cells. Despite their great potential for treating diseases, these types of stem cells present major limitations such as the risk of teratoma formation. In addition, they present other disadvantages such as ethical problems associated with the use of ESCs, safety problems related to iPSC since they requires the use of virus for their production hence limiting its clinical application. For this reason, and in order to solve the current problems in the regeneration of corneal endothelium, this thesis project uses dental pulp stem cells (DPSC) for the formation of CEC. DPSC are an accessible source derived from the same patient, avoiding possible future problems of rejection. In addition, the use of DPSC avoids the ethical and security problems associated with ESC and iPSC. Furthermore, DPSC and CEC have the same embryological origin, as they both arise from neural crest stem cells. In fact, DPSC express neural crest stem cells markers, which facilitates their differentiation into neural crest stem cells (NCSC), which is an intermediate step for the formation of CEC. Therefore, this thesis project uses a two-step protocol, where DPSC are differentiated into NCSC and, subsequently, NCSC are derived into CEC. Because the use of cell therapies alone may present limited cell viability once it is injected, the field of tissue engineering is a new discipline that has appeared to overcome this limitation. Tissue engineering combines the use of cells, biomaterials and biological molecules. It has been demonstrated that the use of different topographies in cell culture modulates cell behavior, and may have an effect on their functionality, cell distribution or cell size. Therefore, this thesis project applies tissue engineering as another strategy for the generation of functional CEC with its characteristic phenotype and morphology. For doing this, we have mimicked the natural CEC environment by cultivating the cells on substrates with different curvatures, composition or topographies that are able to mimic those of the human eye. In conclusion, this thesis project proposes the use of bioengineering, by differentiating CEC from stem cells derived from the patient and the use of biomaterials with different topographies and curvatures, for the regeneration of corneal endothelium.</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="998">
<subfield code="a">si</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="040">
<subfield code="a">ES-BaCBU</subfield>
<subfield code="b">cat</subfield>
<subfield code="e">rda</subfield>
<subfield code="c">ES-BaCBU</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="336">
<subfield code="a">text</subfield>
<subfield code="b">txt</subfield>
<subfield code="2">rdacontent</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="337">
<subfield code="a">informàtic</subfield>
<subfield code="b">c</subfield>
<subfield code="2">rdamedia</subfield>
</datafield>
<datafield ind1=" " ind2=" " tag="338">
<subfield code="a">recurs en línia</subfield>
<subfield code="b">cr</subfield>
<subfield code="2">rdacarrier</subfield>
</datafield>
</record>
<?xml version="1.0" encoding="UTF-8" ?>
<mets ID=" DSpace_ITEM_10803-667398" OBJID=" hdl:10803/667398" PROFILE="DSpace METS SIP Profile 1.0" TYPE="DSpace ITEM" schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd">
<metsHdr CREATEDATE="2022-08-14T18:14:23Z">
<agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
<name>TDX</name>
</agent>
</metsHdr>
<dmdSec ID="DMD_10803_667398">
<mdWrap MDTYPE="MODS">
<xmlData schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:role>
<mods:roleTerm type="text">author</mods:roleTerm>
</mods:role>
<mods:namePart>Bosch Canals, Begoña María</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">authoremail</mods:roleTerm>
</mods:role>
<mods:namePart>bbosch@uic.es</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">authoremailshow</mods:roleTerm>
</mods:role>
<mods:namePart>false</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">director</mods:roleTerm>
</mods:role>
<mods:namePart>Pérez Antoñanzas, Roman</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">director</mods:roleTerm>
</mods:role>
<mods:namePart>Gil Mur, Javier</mods:namePart>
</mods:name>
<mods:name>
<mods:role>
<mods:roleTerm type="text">director</mods:roleTerm>
</mods:role>
<mods:namePart>Sabater, Alfonso</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2019-07-31T14:27:12Z</mods:dateAccessioned>
</mods:extension>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2021-07-15T02:00:13Z</mods:dateAvailable>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2019-07-16</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="uri">http://hdl.handle.net/10803/667398</mods:identifier>
<mods:abstract>Nowadays, there are approximately 10 million people worldwide with visual impairment due to corneal diseases. Currently, the main therapeutic solution is the transplant of a donor's cornea. The great majority of transplants is due to some failure in the inner layer of the cornea, which is called the corneal endothelium and this is mainly related with the inability of this layer to regenerate in vivo. However, transplants present several limitations such as the low number of healthy donors or immunological rejection by the patient. In order to overcome these problems, several researchers have focused in culturing corneal endothelial cells (CEC) to subsequently replace non-functional CEC. However, cell therapy is still very recent and still presents a series of drawbacks. For instance, using animal CEC or cells from other patients has shown to lead into immunological rejection. In order to avoid this, it is possible to use stem cells from the same patient, which have the ability to differentiate into many cell types, including the corneal endothelium. Currently, the stem cells used to regenerate CEC are mainly pluripotent stem cells, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC), which are derived from adult cells. Despite their great potential for treating diseases, these types of stem cells present major limitations such as the risk of teratoma formation. In addition, they present other disadvantages such as ethical problems associated with the use of ESCs, safety problems related to iPSC since they requires the use of virus for their production hence limiting its clinical application. For this reason, and in order to solve the current problems in the regeneration of corneal endothelium, this thesis project uses dental pulp stem cells (DPSC) for the formation of CEC. DPSC are an accessible source derived from the same patient, avoiding possible future problems of rejection. In addition, the use of DPSC avoids the ethical and security problems associated with ESC and iPSC. Furthermore, DPSC and CEC have the same embryological origin, as they both arise from neural crest stem cells. In fact, DPSC express neural crest stem cells markers, which facilitates their differentiation into neural crest stem cells (NCSC), which is an intermediate step for the formation of CEC. Therefore, this thesis project uses a two-step protocol, where DPSC are differentiated into NCSC and, subsequently, NCSC are derived into CEC. Because the use of cell therapies alone may present limited cell viability once it is injected, the field of tissue engineering is a new discipline that has appeared to overcome this limitation. Tissue engineering combines the use of cells, biomaterials and biological molecules. It has been demonstrated that the use of different topographies in cell culture modulates cell behavior, and may have an effect on their functionality, cell distribution or cell size. Therefore, this thesis project applies tissue engineering as another strategy for the generation of functional CEC with its characteristic phenotype and morphology. For doing this, we have mimicked the natural CEC environment by cultivating the cells on substrates with different curvatures, composition or topographies that are able to mimic those of the human eye. In conclusion, this thesis project proposes the use of bioengineering, by differentiating CEC from stem cells derived from the patient and the use of biomaterials with different topographies and curvatures, for the regeneration of corneal endothelium.</mods:abstract>
<mods:language>
<mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
</mods:language>
<mods:subject>
<mods:topic>Tissue engineering</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Corneal endothelium</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Regenerative medicine</mods:topic>
</mods:subject>
<mods:titleInfo>
<mods:title>A bioengineering approach for corneal endothelial regeneration.</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/doctoralThesis</mods:genre>
</mods:mods>
</xmlData>
</mdWrap>
</dmdSec>
<amdSec ID="FO_10803_667398_1">
<techMD ID="TECH_O_10803_667398_1">
<mdWrap MDTYPE="PREMIS">
<xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
<premis:premis>
<premis:object>
<premis:objectIdentifier>
<premis:objectIdentifierType>URL</premis:objectIdentifierType>
<premis:objectIdentifierValue>http://www.tdx.cat/bitstream/10803/667398/1/Tesis%20Bego%c3%b1a%20Mar%c3%ada%20Bosch%20Canals.pdf</premis:objectIdentifierValue>
</premis:objectIdentifier>
<premis:objectCategory>File</premis:objectCategory>
<premis:objectCharacteristics>
<premis:fixity>
<premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
<premis:messageDigest>6805c87119050dd78cc927b313ec6088</premis:messageDigest>
</premis:fixity>
<premis:size>10130883</premis:size>
<premis:format>
<premis:formatDesignation>
<premis:formatName>application/pdf</premis:formatName>
</premis:formatDesignation>
</premis:format>
</premis:objectCharacteristics>
<premis:originalName>Tesis Begoña María Bosch Canals.pdf</premis:originalName>
</premis:object>
</premis:premis>
</xmlData>
</mdWrap>
</techMD>
</amdSec>
<fileSec>
<fileGrp USE="ORIGINAL">
<file ADMID="FO_10803_667398_1" CHECKSUM="6805c87119050dd78cc927b313ec6088" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10803_667398_1" ID="BITSTREAM_ORIGINAL_10803_667398_1" MIMETYPE="application/pdf" SEQ="1" SIZE="10130883">
</file>
</fileGrp>
</fileSec>
<structMap LABEL="DSpace Object" TYPE="LOGICAL">
<div ADMID="DMD_10803_667398" TYPE="DSpace Object Contents">
<div TYPE="DSpace BITSTREAM">
</div>
</div>
</structMap>
</mets>
<?xml version="1.0" encoding="UTF-8" ?>
<mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:namePart>Bosch Canals, Begoña María</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2019-07-31T14:27:12Z</mods:dateAvailable>
</mods:extension>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2021-07-15T02:00:13Z</mods:dateAccessioned>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2019-07-16</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="uri">http://hdl.handle.net/10803/667398</mods:identifier>
<mods:abstract>Nowadays, there are approximately 10 million people worldwide with visual impairment due to corneal diseases. Currently, the main therapeutic solution is the transplant of a donor's cornea. The great majority of transplants is due to some failure in the inner layer of the cornea, which is called the corneal endothelium and this is mainly related with the inability of this layer to regenerate in vivo. However, transplants present several limitations such as the low number of healthy donors or immunological rejection by the patient. In order to overcome these problems, several researchers have focused in culturing corneal endothelial cells (CEC) to subsequently replace non-functional CEC. However, cell therapy is still very recent and still presents a series of drawbacks. For instance, using animal CEC or cells from other patients has shown to lead into immunological rejection. In order to avoid this, it is possible to use stem cells from the same patient, which have the ability to differentiate into many cell types, including the corneal endothelium. Currently, the stem cells used to regenerate CEC are mainly pluripotent stem cells, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC), which are derived from adult cells. Despite their great potential for treating diseases, these types of stem cells present major limitations such as the risk of teratoma formation. In addition, they present other disadvantages such as ethical problems associated with the use of ESCs, safety problems related to iPSC since they requires the use of virus for their production hence limiting its clinical application. For this reason, and in order to solve the current problems in the regeneration of corneal endothelium, this thesis project uses dental pulp stem cells (DPSC) for the formation of CEC. DPSC are an accessible source derived from the same patient, avoiding possible future problems of rejection. In addition, the use of DPSC avoids the ethical and security problems associated with ESC and iPSC. Furthermore, DPSC and CEC have the same embryological origin, as they both arise from neural crest stem cells. In fact, DPSC express neural crest stem cells markers, which facilitates their differentiation into neural crest stem cells (NCSC), which is an intermediate step for the formation of CEC. Therefore, this thesis project uses a two-step protocol, where DPSC are differentiated into NCSC and, subsequently, NCSC are derived into CEC. Because the use of cell therapies alone may present limited cell viability once it is injected, the field of tissue engineering is a new discipline that has appeared to overcome this limitation. Tissue engineering combines the use of cells, biomaterials and biological molecules. It has been demonstrated that the use of different topographies in cell culture modulates cell behavior, and may have an effect on their functionality, cell distribution or cell size. Therefore, this thesis project applies tissue engineering as another strategy for the generation of functional CEC with its characteristic phenotype and morphology. For doing this, we have mimicked the natural CEC environment by cultivating the cells on substrates with different curvatures, composition or topographies that are able to mimic those of the human eye. In conclusion, this thesis project proposes the use of bioengineering, by differentiating CEC from stem cells derived from the patient and the use of biomaterials with different topographies and curvatures, for the regeneration of corneal endothelium.</mods:abstract>
<mods:language>
<mods:languageTerm>eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">info:eu-repo/semantics/openAccess</mods:accessCondition>
<mods:subject>
<mods:topic>Tissue engineering</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Corneal endothelium</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Regenerative medicine</mods:topic>
</mods:subject>
<mods:titleInfo>
<mods:title>A bioengineering approach for corneal endothelial regeneration.</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/doctoralThesis</mods:genre>
<mods:genre>info:eu-repo/semantics/publishedVersion</mods:genre>
</mods:mods>
<?xml version="1.0" encoding="UTF-8" ?>
<atom:entry schemaLocation="http://www.w3.org/2005/Atom http://www.kbcafe.com/rss/atom.xsd.xml">
<atom:id>http://hdl.handle.net/10803/667398/ore.xml</atom:id>
<atom:published>2021-07-15T02:00:13Z</atom:published>
<atom:updated>2019-07-31T14:27:12Z</atom:updated>
<atom:source>
<atom:generator>TDX</atom:generator>
</atom:source>
<atom:title>A bioengineering approach for corneal endothelial regeneration.</atom:title>
<atom:author>
<atom:name>Bosch Canals, Begoña María</atom:name>
</atom:author>
<oreatom:triples>
<rdf:Description about="http://hdl.handle.net/10803/667398/ore.xml#atom">
<dcterms:modified>2019-07-31T14:27:12Z</dcterms:modified>
</rdf:Description>
<rdf:Description about="http://www.tdx.cat/bitstream/10803/667398/5/Tesis%20Bego%c3%b1a%20Mar%c3%ada%20Bosch%20Canals.pdf.xml">
<dcterms:description>MEDIA_DOCUMENT</dcterms:description>
</rdf:Description>
<rdf:Description about="http://www.tdx.cat/bitstream/10803/667398/2/license_url">
<dcterms:description>CC-LICENSE</dcterms:description>
</rdf:Description>
<rdf:Description about="http://www.tdx.cat/bitstream/10803/667398/3/license_text">
<dcterms:description>CC-LICENSE</dcterms:description>
</rdf:Description>
<rdf:Description about="http://www.tdx.cat/bitstream/10803/667398/4/license_rdf">
<dcterms:description>CC-LICENSE</dcterms:description>
</rdf:Description>
<rdf:Description about="http://www.tdx.cat/bitstream/10803/667398/1/Tesis%20Bego%c3%b1a%20Mar%c3%ada%20Bosch%20Canals.pdf">
<dcterms:description>ORIGINAL</dcterms:description>
</rdf:Description>
</oreatom:triples>
</atom:entry>
<?xml version="1.0" encoding="UTF-8" ?>
<qdc:qualifieddc schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
<dc:title>A bioengineering approach for corneal endothelial regeneration.</dc:title>
<dc:creator>Bosch Canals, Begoña María</dc:creator>
<dc:contributor>Pérez Antoñanzas, Roman</dc:contributor>
<dc:contributor>Gil Mur, Javier</dc:contributor>
<dc:contributor>Sabater, Alfonso</dc:contributor>
<dc:subject>Tissue engineering</dc:subject>
<dc:subject>Corneal endothelium</dc:subject>
<dc:subject>Regenerative medicine</dc:subject>
<dcterms:abstract>Nowadays, there are approximately 10 million people worldwide with visual impairment due to corneal diseases. Currently, the main therapeutic solution is the transplant of a donor's cornea. The great majority of transplants is due to some failure in the inner layer of the cornea, which is called the corneal endothelium and this is mainly related with the inability of this layer to regenerate in vivo. However, transplants present several limitations such as the low number of healthy donors or immunological rejection by the patient. In order to overcome these problems, several researchers have focused in culturing corneal endothelial cells (CEC) to subsequently replace non-functional CEC. However, cell therapy is still very recent and still presents a series of drawbacks. For instance, using animal CEC or cells from other patients has shown to lead into immunological rejection. In order to avoid this, it is possible to use stem cells from the same patient, which have the ability to differentiate into many cell types, including the corneal endothelium. Currently, the stem cells used to regenerate CEC are mainly pluripotent stem cells, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC), which are derived from adult cells. Despite their great potential for treating diseases, these types of stem cells present major limitations such as the risk of teratoma formation. In addition, they present other disadvantages such as ethical problems associated with the use of ESCs, safety problems related to iPSC since they requires the use of virus for their production hence limiting its clinical application. For this reason, and in order to solve the current problems in the regeneration of corneal endothelium, this thesis project uses dental pulp stem cells (DPSC) for the formation of CEC. DPSC are an accessible source derived from the same patient, avoiding possible future problems of rejection. In addition, the use of DPSC avoids the ethical and security problems associated with ESC and iPSC. Furthermore, DPSC and CEC have the same embryological origin, as they both arise from neural crest stem cells. In fact, DPSC express neural crest stem cells markers, which facilitates their differentiation into neural crest stem cells (NCSC), which is an intermediate step for the formation of CEC. Therefore, this thesis project uses a two-step protocol, where DPSC are differentiated into NCSC and, subsequently, NCSC are derived into CEC. Because the use of cell therapies alone may present limited cell viability once it is injected, the field of tissue engineering is a new discipline that has appeared to overcome this limitation. Tissue engineering combines the use of cells, biomaterials and biological molecules. It has been demonstrated that the use of different topographies in cell culture modulates cell behavior, and may have an effect on their functionality, cell distribution or cell size. Therefore, this thesis project applies tissue engineering as another strategy for the generation of functional CEC with its characteristic phenotype and morphology. For doing this, we have mimicked the natural CEC environment by cultivating the cells on substrates with different curvatures, composition or topographies that are able to mimic those of the human eye. In conclusion, this thesis project proposes the use of bioengineering, by differentiating CEC from stem cells derived from the patient and the use of biomaterials with different topographies and curvatures, for the regeneration of corneal endothelium.</dcterms:abstract>
<dcterms:dateAccepted>2021-07-15T02:00:13Z</dcterms:dateAccepted>
<dcterms:available>2021-07-15T02:00:13Z</dcterms:available>
<dcterms:created>2021-07-15T02:00:13Z</dcterms:created>
<dcterms:issued>2019-07-16</dcterms:issued>
<dc:type>info:eu-repo/semantics/doctoralThesis</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:identifier>http://hdl.handle.net/10803/667398</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights>L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:publisher>Universitat Internacional de Catalunya</dc:publisher>
<dc:source>TDX (Tesis Doctorals en Xarxa)</dc:source>
</qdc:qualifieddc>
<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
<ow:Publication about="oai:www.tdx.cat:10803/667398">
<dc:title>A bioengineering approach for corneal endothelial regeneration.</dc:title>
<dc:creator>Bosch Canals, Begoña María</dc:creator>
<dc:contributor>bbosch@uic.es</dc:contributor>
<dc:contributor>false</dc:contributor>
<dc:contributor>Pérez Antoñanzas, Roman</dc:contributor>
<dc:contributor>Gil Mur, Javier</dc:contributor>
<dc:contributor>Sabater, Alfonso</dc:contributor>
<dc:subject>Tissue engineering</dc:subject>
<dc:subject>Corneal endothelium</dc:subject>
<dc:subject>Regenerative medicine</dc:subject>
<dc:description>Nowadays, there are approximately 10 million people worldwide with visual impairment due to corneal diseases. Currently, the main therapeutic solution is the transplant of a donor's cornea. The great majority of transplants is due to some failure in the inner layer of the cornea, which is called the corneal endothelium and this is mainly related with the inability of this layer to regenerate in vivo. However, transplants present several limitations such as the low number of healthy donors or immunological rejection by the patient. In order to overcome these problems, several researchers have focused in culturing corneal endothelial cells (CEC) to subsequently replace non-functional CEC. However, cell therapy is still very recent and still presents a series of drawbacks. For instance, using animal CEC or cells from other patients has shown to lead into immunological rejection. In order to avoid this, it is possible to use stem cells from the same patient, which have the ability to differentiate into many cell types, including the corneal endothelium. Currently, the stem cells used to regenerate CEC are mainly pluripotent stem cells, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC), which are derived from adult cells. Despite their great potential for treating diseases, these types of stem cells present major limitations such as the risk of teratoma formation. In addition, they present other disadvantages such as ethical problems associated with the use of ESCs, safety problems related to iPSC since they requires the use of virus for their production hence limiting its clinical application. For this reason, and in order to solve the current problems in the regeneration of corneal endothelium, this thesis project uses dental pulp stem cells (DPSC) for the formation of CEC. DPSC are an accessible source derived from the same patient, avoiding possible future problems of rejection. In addition, the use of DPSC avoids the ethical and security problems associated with ESC and iPSC. Furthermore, DPSC and CEC have the same embryological origin, as they both arise from neural crest stem cells. In fact, DPSC express neural crest stem cells markers, which facilitates their differentiation into neural crest stem cells (NCSC), which is an intermediate step for the formation of CEC. Therefore, this thesis project uses a two-step protocol, where DPSC are differentiated into NCSC and, subsequently, NCSC are derived into CEC. Because the use of cell therapies alone may present limited cell viability once it is injected, the field of tissue engineering is a new discipline that has appeared to overcome this limitation. Tissue engineering combines the use of cells, biomaterials and biological molecules. It has been demonstrated that the use of different topographies in cell culture modulates cell behavior, and may have an effect on their functionality, cell distribution or cell size. Therefore, this thesis project applies tissue engineering as another strategy for the generation of functional CEC with its characteristic phenotype and morphology. For doing this, we have mimicked the natural CEC environment by cultivating the cells on substrates with different curvatures, composition or topographies that are able to mimic those of the human eye. In conclusion, this thesis project proposes the use of bioengineering, by differentiating CEC from stem cells derived from the patient and the use of biomaterials with different topographies and curvatures, for the regeneration of corneal endothelium.</dc:description>
<dc:date>2019-07-31T14:27:12Z</dc:date>
<dc:date>2021-07-15T02:00:13Z</dc:date>
<dc:date>2019-07-16</dc:date>
<dc:type>info:eu-repo/semantics/doctoralThesis</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:identifier>http://hdl.handle.net/10803/667398</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights>L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:publisher>Universitat Internacional de Catalunya</dc:publisher>
<dc:source>TDX (Tesis Doctorals en Xarxa)</dc:source>
</ow:Publication>
</rdf:RDF>
<?xml version="1.0" encoding="UTF-8" ?>
<uketd_dc:uketddc schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
<dc:title>A bioengineering approach for corneal endothelial regeneration.</dc:title>
<dc:creator>Bosch Canals, Begoña María</dc:creator>
<dcterms:abstract>Nowadays, there are approximately 10 million people worldwide with visual impairment due to corneal diseases. Currently, the main therapeutic solution is the transplant of a donor's cornea. The great majority of transplants is due to some failure in the inner layer of the cornea, which is called the corneal endothelium and this is mainly related with the inability of this layer to regenerate in vivo. However, transplants present several limitations such as the low number of healthy donors or immunological rejection by the patient. In order to overcome these problems, several researchers have focused in culturing corneal endothelial cells (CEC) to subsequently replace non-functional CEC. However, cell therapy is still very recent and still presents a series of drawbacks. For instance, using animal CEC or cells from other patients has shown to lead into immunological rejection. In order to avoid this, it is possible to use stem cells from the same patient, which have the ability to differentiate into many cell types, including the corneal endothelium. Currently, the stem cells used to regenerate CEC are mainly pluripotent stem cells, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC), which are derived from adult cells. Despite their great potential for treating diseases, these types of stem cells present major limitations such as the risk of teratoma formation. In addition, they present other disadvantages such as ethical problems associated with the use of ESCs, safety problems related to iPSC since they requires the use of virus for their production hence limiting its clinical application. For this reason, and in order to solve the current problems in the regeneration of corneal endothelium, this thesis project uses dental pulp stem cells (DPSC) for the formation of CEC. DPSC are an accessible source derived from the same patient, avoiding possible future problems of rejection. In addition, the use of DPSC avoids the ethical and security problems associated with ESC and iPSC. Furthermore, DPSC and CEC have the same embryological origin, as they both arise from neural crest stem cells. In fact, DPSC express neural crest stem cells markers, which facilitates their differentiation into neural crest stem cells (NCSC), which is an intermediate step for the formation of CEC. Therefore, this thesis project uses a two-step protocol, where DPSC are differentiated into NCSC and, subsequently, NCSC are derived into CEC. Because the use of cell therapies alone may present limited cell viability once it is injected, the field of tissue engineering is a new discipline that has appeared to overcome this limitation. Tissue engineering combines the use of cells, biomaterials and biological molecules. It has been demonstrated that the use of different topographies in cell culture modulates cell behavior, and may have an effect on their functionality, cell distribution or cell size. Therefore, this thesis project applies tissue engineering as another strategy for the generation of functional CEC with its characteristic phenotype and morphology. For doing this, we have mimicked the natural CEC environment by cultivating the cells on substrates with different curvatures, composition or topographies that are able to mimic those of the human eye. In conclusion, this thesis project proposes the use of bioengineering, by differentiating CEC from stem cells derived from the patient and the use of biomaterials with different topographies and curvatures, for the regeneration of corneal endothelium.</dcterms:abstract>
<uketdterms:institution>Universitat Internacional de Catalunya</uketdterms:institution>
<dcterms:issued>2019-07-16</dcterms:issued>
<dc:type>info:eu-repo/semantics/doctoralThesis</dc:type>
<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
<dc:language type="dcterms:ISO639-2">eng</dc:language>
<dcterms:isReferencedBy>http://hdl.handle.net/10803/667398</dcterms:isReferencedBy>
<dc:identifier type="dcterms:URI">http://www.tdx.cat/bitstream/10803/667398/1/Tesis%20Bego%c3%b1a%20Mar%c3%ada%20Bosch%20Canals.pdf</dc:identifier>
<uketdterms:checksum type="uketdterms:MD5">6805c87119050dd78cc927b313ec6088</uketdterms:checksum>
<uketdterms:embargodate>24 mesos</uketdterms:embargodate>
<dc:subject>Tissue engineering</dc:subject>
<dc:subject>Corneal endothelium</dc:subject>
<dc:subject>Regenerative medicine</dc:subject>
<dc:subject>Bioingeniería y medicina regenerativa</dc:subject>
</uketd_dc:uketddc>
<?xml version="1.0" encoding="UTF-8" ?>
<metadata schemaLocation="http://www.lyncode.com/xoai http://www.lyncode.com/xsd/xoai.xsd">
<element name="dc">
<element name="contributor">
<element name="none">
<field name="value">Universitat Internacional de Catalunya. Departament de Ciències Bàsiques</field>
</element>
<element name="author">
<element name="none">
<field name="value">Bosch Canals, Begoña María</field>
</element>
</element>
<element name="authoremail">
<element name="en_US">
<field name="value">bbosch@uic.es</field>
</element>
</element>
<element name="authoremailshow">
<element name="en_US">
<field name="value">false</field>
</element>
</element>
<element name="director">
<element name="none">
<field name="value">Pérez Antoñanzas, Roman</field>
<field name="value">Gil Mur, Javier</field>
<field name="value">Sabater, Alfonso</field>
</element>
</element>
</element>
<element name="date">
<element name="accessioned">
<element name="none">
<field name="value">2019-07-31T14:27:12Z</field>
</element>
</element>
<element name="available">
<element name="none">
<field name="value">2021-07-15T02:00:13Z</field>
</element>
</element>
<element name="issued">
<element name="none">
<field name="value">2019-07-16</field>
</element>
</element>
</element>
<element name="identifier">
<element name="uri">
<element name="none">
<field name="value">http://hdl.handle.net/10803/667398</field>
</element>
</element>
</element>
<element name="description">
<element name="abstract">
<element name="en_US">
<field name="value">Nowadays, there are approximately 10 million people worldwide with visual impairment due to corneal diseases. Currently, the main therapeutic solution is the transplant of a donor's cornea. The great majority of transplants is due to some failure in the inner layer of the cornea, which is called the corneal endothelium and this is mainly related with the inability of this layer to regenerate in vivo. However, transplants present several limitations such as the low number of healthy donors or immunological rejection by the patient. In order to overcome these problems, several researchers have focused in culturing corneal endothelial cells (CEC) to subsequently replace non-functional CEC. However, cell therapy is still very recent and still presents a series of drawbacks. For instance, using animal CEC or cells from other patients has shown to lead into immunological rejection. In order to avoid this, it is possible to use stem cells from the same patient, which have the ability to differentiate into many cell types, including the corneal endothelium. Currently, the stem cells used to regenerate CEC are mainly pluripotent stem cells, either embryonic stem cells (ESC) or induced pluripotent stem cells (iPSC), which are derived from adult cells. Despite their great potential for treating diseases, these types of stem cells present major limitations such as the risk of teratoma formation. In addition, they present other disadvantages such as ethical problems associated with the use of ESCs, safety problems related to iPSC since they requires the use of virus for their production hence limiting its clinical application. For this reason, and in order to solve the current problems in the regeneration of corneal endothelium, this thesis project uses dental pulp stem cells (DPSC) for the formation of CEC. DPSC are an accessible source derived from the same patient, avoiding possible future problems of rejection. In addition, the use of DPSC avoids the ethical and security problems associated with ESC and iPSC. Furthermore, DPSC and CEC have the same embryological origin, as they both arise from neural crest stem cells. In fact, DPSC express neural crest stem cells markers, which facilitates their differentiation into neural crest stem cells (NCSC), which is an intermediate step for the formation of CEC. Therefore, this thesis project uses a two-step protocol, where DPSC are differentiated into NCSC and, subsequently, NCSC are derived into CEC. Because the use of cell therapies alone may present limited cell viability once it is injected, the field of tissue engineering is a new discipline that has appeared to overcome this limitation. Tissue engineering combines the use of cells, biomaterials and biological molecules. It has been demonstrated that the use of different topographies in cell culture modulates cell behavior, and may have an effect on their functionality, cell distribution or cell size. Therefore, this thesis project applies tissue engineering as another strategy for the generation of functional CEC with its characteristic phenotype and morphology. For doing this, we have mimicked the natural CEC environment by cultivating the cells on substrates with different curvatures, composition or topographies that are able to mimic those of the human eye. In conclusion, this thesis project proposes the use of bioengineering, by differentiating CEC from stem cells derived from the patient and the use of biomaterials with different topographies and curvatures, for the regeneration of corneal endothelium.</field>
</element>
</element>
</element>
<element name="format">
<element name="extent">
<element name="en_US">
<field name="value">206 p.</field>
</element>
</element>
<element name="mimetype">
<element name="none">
<field name="value">application/pdf</field>
</element>
</element>
</element>
<element name="language">
<element name="iso">
<element name="en_US">
<field name="value">eng</field>
</element>
</element>
</element>
<element name="publisher">
<element name="none">
<field name="value">Universitat Internacional de Catalunya</field>
</element>
</element>
<element name="rights">
<element name="license">
<element name="none">
<field name="value">L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: http://creativecommons.org/licenses/by-nc-nd/4.0/</field>
</element>
</element>
<element name="accessLevel">
<element name="none">
<field name="value">info:eu-repo/semantics/openAccess</field>
</element>
</element>
</element>
<element name="source">
<element name="none">
<field name="value">TDX (Tesis Doctorals en Xarxa)</field>
</element>
</element>
<element name="subject">
<element name="en_US">
<field name="value">Tissue engineering</field>
<field name="value">Corneal endothelium</field>
<field name="value">Regenerative medicine</field>
</element>
<element name="other">
<element name="en_US">
<field name="value">Bioingeniería y medicina regenerativa</field>
</element>
</element>
<element name="udc">
<element name="en_US">
<field name="value">61</field>
</element>
</element>
</element>
<element name="title">
<element name="en_US">
<field name="value">A bioengineering approach for corneal endothelial regeneration.</field>
</element>
</element>
<element name="type">
<element name="none">
<field name="value">info:eu-repo/semantics/doctoralThesis</field>
<field name="value">info:eu-repo/semantics/publishedVersion</field>
</element>
</element>
<element name="embargo">
<element name="terms">
<element name="en_US">
<field name="value">24 mesos</field>
</element>
</element>
</element>
</element>
<element name="bundles">
<element name="bundle">
<field name="name">MEDIA_DOCUMENT</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">Tesis Begoña María Bosch Canals.pdf.xml</field>
<field name="originalName">Tesis Begoña María Bosch Canals.pdf.xml</field>
<field name="description">Document Consulta</field>
<field name="format">text/xml</field>
<field name="size">106</field>
<field name="url">http://www.tdx.cat/bitstream/10803/667398/5/Tesis%20Bego%c3%b1a%20Mar%c3%ada%20Bosch%20Canals.pdf.xml</field>
<field name="checksum">0e2d508f21db7fd129a6823caf477bb4</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">5</field>
</element>
</element>
</element>
<element name="bundle">
<field name="name">CC-LICENSE</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">license_url</field>
<field name="originalName">license_url</field>
<field name="format">text/plain; charset=utf-8</field>
<field name="size">49</field>
<field name="url">http://www.tdx.cat/bitstream/10803/667398/2/license_url</field>
<field name="checksum">4afdbb8c545fd630ea7db775da747b2f</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">2</field>
</element>
<element name="bitstream">
<field name="name">license_text</field>
<field name="originalName">license_text</field>
<field name="format">text/html; charset=utf-8</field>
<field name="size">0</field>
<field name="url">http://www.tdx.cat/bitstream/10803/667398/3/license_text</field>
<field name="checksum">d41d8cd98f00b204e9800998ecf8427e</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">3</field>
</element>
<element name="bitstream">
<field name="name">license_rdf</field>
<field name="originalName">license_rdf</field>
<field name="format">application/rdf+xml; charset=utf-8</field>
<field name="size">0</field>
<field name="url">http://www.tdx.cat/bitstream/10803/667398/4/license_rdf</field>
<field name="checksum">d41d8cd98f00b204e9800998ecf8427e</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">4</field>
</element>
</element>
</element>
<element name="bundle">
<field name="name">ORIGINAL</field>
<element name="bitstreams">
<element name="bitstream">
<field name="name">Tesis Begoña María Bosch Canals.pdf</field>
<field name="originalName">Tesis Begoña María Bosch Canals.pdf</field>
<field name="format">application/pdf</field>
<field name="size">10130883</field>
<field name="url">http://www.tdx.cat/bitstream/10803/667398/1/Tesis%20Bego%c3%b1a%20Mar%c3%ada%20Bosch%20Canals.pdf</field>
<field name="checksum">6805c87119050dd78cc927b313ec6088</field>
<field name="checksumAlgorithm">MD5</field>
<field name="sid">1</field>
</element>
</element>
</element>
</element>
<element name="others">
<field name="handle">10803/667398</field>
<field name="identifier">oai:www.tdx.cat:10803/667398</field>
<field name="lastModifyDate">2021-07-15 04:00:13.772</field>
</element>
<element name="repository">
<field name="name">TDX</field>
<field name="mail">tdx@csuc.cat</field>
</element>
</metadata>